You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 278 No. 5, August 6, 1997 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Special Communications
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Bioterrorism
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Iraq's Biological Weapons

The Past as Future?

Raymond A. Zilinskas, PhD

JAMA. 1997;278(5):418-424.


Abstract

Between 1985 and April 1991, Iraq developed anthrax, botulinum toxin, and aflatoxin for biological warfare; 200 bombs and 25 ballistic missiles laden with biological agents were deployed by the time Operation Desert Storm occurred. Although cause for concern, if used during the Persian Gulf War, Iraq's biological warfare arsenal probably would have been militarily ineffective for 3 reasons: (1) it was small; (2) payload dispersal mechanisms were inefficient; and (3) coalition forces dominated the theater of war (ie, they had overwhelming air superiority and had crippled Iraq's command and control capability). Despite the Gulf War defeat, the Iraqi biological warfare threat has not been extinguished. Saddam Hussein remains in power, and his desire to acquire weapons of mass destruction continues unabated. In this context, the international community must be firm in its enforcement of United Nations resolutions designed to deter Iraq from reacquiring biological warfare capability and must take steps to develop a multidisciplinary approach to limiting future development of weapons of mass destruction.



Author Affiliations

From the Center for Public Issues in Biotechnology, University of Maryland Biotechnology Institute, College Park.


Footnotes

All of the opinions and analyses expressed in this article are the author's own and do not necessarily reflect or agree with those of the agencies or organizations with which he has been associated.

Reprints: Raymond A. Zilinskas, PhD, Center for Public Issues in Biotechnology, University of Maryland Biotechnology Institute, 4321 Hartwick Rd, Suite 500, College Park, MD 20740.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pulmonary Inflammation Triggered by Ricin Toxin Requires Macrophages and IL-1 Signaling
Lindauer et al.
J. Immunol. 2009;183:1419-1426.
ABSTRACT | FULL TEXT  

Anthrax Vaccine and Public Health Policy
Weiss et al.
AJPH 2007;97:1945-1951.
ABSTRACT | FULL TEXT  

Ricin Poisoning: A Comprehensive Review
Audi et al.
JAMA 2005;294:2342-2351.
ABSTRACT | FULL TEXT  

Characterization of Botulinum Progenitor Toxins by Mass Spectrometry
Hines et al.
Appl. Environ. Microbiol. 2005;71:4478-4486.
ABSTRACT | FULL TEXT  

Pharmacy Preparedness for Incidents Involving Nuclear, Biological, or Chemical Weapons
Burda and Sigg
Journal of Pharmacy Practice 2004;17:251-265.
ABSTRACT  

Gulf War Veterans and Iraqi Nerve Agents at Khamisiyah: Postwar Hospitalization Data Revisited
Smith et al.
Am J Epidemiol 2003;158:457-467.
ABSTRACT | FULL TEXT  

Novel Sample Preparation Method for Safe and Rapid Detection of Bacillus anthracis Spores in Environmental Powders and Nasal Swabs
Luna et al.
J. Clin. Microbiol. 2003;41:1252-1255.
ABSTRACT | FULL TEXT  

Indoor Mold, Toxigenic Fungi, and Stachybotrys chartarum: Infectious Disease Perspective
Kuhn and Ghannoum
Clin. Microbiol. Rev. 2003;16:144-172.
ABSTRACT | FULL TEXT  

Analytic Reviews: Management of Patients Exposed to Biological and Chemical Warfare Agents
Marik and Bowles
J Intensive Care Med 2002;17:147-161.
ABSTRACT  

Confronting Bioterrorism: Physicians on the Front Line
Varkey et al.
Mayo Clin Proc. 2002;77:661-672.
ABSTRACT  

Anthrax as a Biological Weapon, 2002: Updated Recommendations for Management
Inglesby et al.
JAMA 2002;287:2236-2252.
ABSTRACT | FULL TEXT  

Large-Scale Quarantine Following Biological Terrorism in the United States: Scientific Examination, Logistic and Legal Limits, and Possible Consequences
Barbera et al.
JAMA 2001;286:2711-2717.
ABSTRACT | FULL TEXT  

Bioterrorism
Bellamy and Freedman
QJM 2001;94:227-234.
FULL TEXT  

Botulinum Toxin as a Biological Weapon: Medical and Public Health Management
Arnon et al.
JAMA 2001;285:1059-1070.
ABSTRACT | FULL TEXT  

Pharmacy Preparedness for Incidents Involving Weapons of Mass Destruction
Burda and Sigg
Journal of Pharmacy Practice 2000;13:141-155.
ABSTRACT  

In Vitro Selection of RNA Molecules That Inhibit the Activity of Ricin A-chain
Hesselberth et al.
J. Biol. Chem. 2000;275:4937-4942.
ABSTRACT | FULL TEXT  

Anthrax as a Biological Weapon: Medical and Public Health Management
Inglesby et al.
JAMA 1999;281:1735-1745.
ABSTRACT | FULL TEXT  

Cutaneous Manifestations of Biological Warfare and Related Threat Agents
McGovern et al.
Arch Dermatol 1999;135:311-322.
ABSTRACT | FULL TEXT  

The Looming Threat of Bioterrorism
Henderson
Science 1999;283:1279-1282.
ABSTRACT | FULL TEXT  

Poxvirus Dilemmas -- Monkeypox, Smallpox, and Biologic Terrorism
Breman and Henderson
NEJM 1998;339:556-559.
FULL TEXT  

Biological Weapons Control: Prospects and Implications for the Future
Kadlec et al.
JAMA 1997;278:351-356.
ABSTRACT  

Biological Warfare: A Historical Perspective
Christopher et al.
JAMA 1997;278:412-417.
ABSTRACT  

Why Should We Be Concerned About Biological Warfare?
Danzig and Berkowsky
JAMA 1997;278:431-432.
ABSTRACT  

Infectious Disease and Biological Weapons: Prophylaxis and Mitigation
Lederberg
JAMA 1997;278:435-436.
ABSTRACT  

Recognition and Management of Anthrax -- An Update
Swartz
NEJM 2001;345:1621-1626.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.